JP2023504547A - アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 - Google Patents

アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Download PDF

Info

Publication number
JP2023504547A
JP2023504547A JP2022533470A JP2022533470A JP2023504547A JP 2023504547 A JP2023504547 A JP 2023504547A JP 2022533470 A JP2022533470 A JP 2022533470A JP 2022533470 A JP2022533470 A JP 2022533470A JP 2023504547 A JP2023504547 A JP 2023504547A
Authority
JP
Japan
Prior art keywords
subject
active agent
unit dosage
dosage form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504547A5 (https=
Inventor
ジョン パトリック ジュニア ケイシー，
デイビッド アーサー ベリー，
ティモシー エフ． ブリッグス，
レナード バックビンダー，
ミ－ジョン キム，
アンナ リャン，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Publication of JP2023504547A publication Critical patent/JP2023504547A/ja
Publication of JP2023504547A5 publication Critical patent/JP2023504547A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2022533470A 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Pending JP2023504547A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US62/944,282 2019-12-05
US202063074785P 2020-09-04 2020-09-04
US63/074,785 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2023504547A true JP2023504547A (ja) 2023-02-03
JP2023504547A5 JP2023504547A5 (https=) 2023-12-11

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533470A Pending JP2023504547A (ja) 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法

Country Status (8)

Country Link
US (1) US20220296563A1 (https=)
EP (1) EP4069209A4 (https=)
JP (1) JP2023504547A (https=)
CN (1) CN114901267A (https=)
AU (1) AU2020396554A1 (https=)
BR (1) BR112022010672A2 (https=)
CA (1) CA3163342A1 (https=)
WO (1) WO2021113620A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330612A (ja) * 1994-06-08 1995-12-19 Synthelabo Sa メトクロプラミドおよびパラセタモールまたはアセチルサリチル酸誘導体を含有する粉末剤
JPH10509982A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するｎｓａｉｄの導入
JP2002505678A (ja) * 1997-06-24 2002-02-19 クロイツ、ヴェルナー 腫瘍組織を選択的に制御するための、相乗効果を有する組成物
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
PT2056815E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite
US8834858B2 (en) * 2010-07-02 2014-09-16 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
CA3102404A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP3801489A4 (en) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330612A (ja) * 1994-06-08 1995-12-19 Synthelabo Sa メトクロプラミドおよびパラセタモールまたはアセチルサリチル酸誘導体を含有する粉末剤
JPH10509982A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するｎｓａｉｄの導入
JP2002505678A (ja) * 1997-06-24 2002-02-19 クロイツ、ヴェルナー 腫瘍組織を選択的に制御するための、相乗効果を有する組成物
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
山田 勝久 他: "ジアセチルゲンチシン酸のメラニン生成抑制作用に関する研究", 日本香粧品科学会誌, vol. 22, JPN6024053202, 1998, pages 169 - 174, ISSN: 0005650157 *

Also Published As

Publication number Publication date
BR112022010672A2 (pt) 2022-08-16
CN114901267A (zh) 2022-08-12
US20220296563A1 (en) 2022-09-22
AU2020396554A1 (en) 2022-07-07
EP4069209A4 (en) 2024-04-10
CA3163342A1 (en) 2021-06-10
WO2021113620A8 (en) 2021-07-22
EP4069209A1 (en) 2022-10-12
WO2021113620A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7377220B2 (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
EP3681862B1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US10676438B2 (en) KCNQ2-5 channel activator
EP3560926B1 (en) 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors
WO2009140642A2 (en) Tricyclic antagonists of prostaglandin d2 receptors
CN119241632A (zh) 雷公藤红素的类似物
CA2873104A1 (en) Compositions and methods for the treatment of mucositis
JP2004522710A (ja) 性機能障害の治療
CN104684889A (zh) 二甲双胍的三盐形式
EP4470540A1 (en) Use of heterocyclic compound
RU2382029C2 (ru) Новые производные циклогексана
JP6138150B2 (ja) ［１，２，４］トリアゾロピリジンおよびホスホジエステラーゼ阻害剤としてのその使用
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
US6924295B2 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
CN101821227A (zh) 激素敏感性脂酶调节剂及使用方法
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
JP2018009019A (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
TW202023535A (zh) Dp拮抗劑
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
JP2023504547A (ja) アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法
JP2023505233A (ja) アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法
CN104557944B (zh) 一种降糖药物及其制备方法
US11958869B2 (en) Ruthenium arene Schiff-base complexes and uses thereof
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
CN101386617B (zh) 取代的四氢异喹啉衍生物、其制备方法及含有它们的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250728